Firefly Bio

Firefly Bio develops a novel platform to treat cancer using degrader antibody conjugates (DACs). Their proprietary Firelink linker technology combines the strengths of antibody drug conjugates (ADCs) and protein degraders, overcoming limitations of each to create a new class of highly specific and effective cancer therapeutics. This platform enables DACs at scale, vastly expanding the number of payloads for ADCs.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: $94M

Date: 15-Feb-2024

Investors: Versant Ventures, MPM BioImpact, Decheng Capital, Eli Lilly & Company

Markets: Biotechnology, Oncology, Immunology, Medical, Drug Discovery, HealthTech, Life Sciences

HQ: South San Francisco, California, United States

Founded: 2022

Website: https://fireflybiologics.com/

LinkedIn: https://www.linkedin.com/company/firefly-biologics

Twitter:

Instagram: